Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

Carmen Balana,Carlos Mesia Barroso,Sonia del Barco Berrón,Estela Pineda Losada,José Muñoz Langa,A. Estival,Ramon De Las Penas,José Luis Fuster,Miguel Gil,L Miguel Navarro,Miriam Crespo Alonso,Ana Herrero,María Ángeles Vaz Salgado,Sergi Peralta,Clara Olier,Pedro Pérez-Segura,Marta Covela Rúa,Cristina Carrato,Carolina Sanz,Juan M. Sepulveda-Sánchez

Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

2019

2001Background: The GEINO-14-01 trial (NCT02209948) investigated the role of extending temozolomide (TMZ) for 6 cycles after the standard 6 cycles to improve 6m-PFS, SLP and OS in newly diagnosed g...

Keywords:

Clinical trial
Temozolomide
Glioblastoma
Continuation
Medicine
Internal medicine
Oncology
newly diagnosed
first line treatment
in patient
neuro oncology
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations